Literature DB >> 10574259

Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast.

S Regele1, P Kohlberger, F D Vogl, W Böhm, R Kreienberg, I B Runnebaum.   

Abstract

Five of 43 patients (11.6%) with ductal carcinoma in situ of the breast presented with p53 autoantibodies at diagnosis. Three seropositive patients demonstrated tumour sizes of < or = 5 mm. There was no association of p53 autoantibody status with age, clinical presentation, histological subtype, tumour size, grading, p53 immunohistochemistry or hormone receptor status.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10574259      PMCID： PMC2362899          DOI： 10.1038/sj.bjc.6690751

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  17 in total

1.  Screening for breast cancer in Nijmegen. Report of 6 screening rounds, 1975-1986.

Authors:  P H Peeters; A L Verbeek; J H Hendriks; M J van Bon
Journal:  Int J Cancer       Date:  1989-02-15       Impact factor: 7.396

2.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue].

Authors:  W Remmele; H E Stegner
Journal:  Pathologe       Date:  1987-05       Impact factor: 1.011

Review 3.  Ductal carcinoma in situ (intraductal carcinoma) of the breast.

Authors:  S J Schnitt; W Silen; N L Sadowsky; J L Connolly; J R Harris
Journal:  N Engl J Med       Date:  1988-04-07       Impact factor: 91.245

4.  Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer.

Authors:  J P Peyrat; J Bonneterre; R Lubin; L Vanlemmens; J Fournier; T Soussi
Journal:  Lancet       Date:  1995-03-11       Impact factor: 79.321

5.  Humoral immune response against p53 protein in patients with colorectal carcinoma.

Authors:  K Angelopoulou; M Stratis; E P Diamandis
Journal:  Int J Cancer       Date:  1997-01-06       Impact factor: 7.396

6.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer.

Authors:  L V Crawford; D C Pim; R D Bulbrook
Journal:  Int J Cancer       Date:  1982-10-15       Impact factor: 7.396

7.  [Antibody formation to cellular p53 protein in patients with squamous cell carcinomas of the upper respiratory and digestive system].

Authors:  J D Maass; S Gottschlich; B M Lippert; A M Niemann; T Görögh; J A Werner
Journal:  Laryngorhinootologie       Date:  1996-01       Impact factor: 1.057

8.  Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers.

Authors:  K Angelopoulou; E P Diamandis; D J Sutherland; J A Kellen; P S Bunting
Journal:  Int J Cancer       Date:  1994-08-15       Impact factor: 7.396

9.  The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.

Authors:  S Sjögren; M Inganäs; T Norberg; A Lindgren; H Nordgren; L Holmberg; J Bergh
Journal:  J Natl Cancer Inst       Date:  1996-02-21       Impact factor: 13.506

10.  The relationship between serum p53 autoantibodies and characteristics of human breast cancer.

Authors:  B Mudenda; J A Green; B Green; J R Jenkins; L Robertson; M Tarunina; S J Leinster
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640
View more
  5 in total

1.  Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera.

Authors:  Hailing Lu; Jon Ladd; Ziding Feng; Mei Wu; Vivian Goodell; Sharon J Pitteri; Christopher I Li; Ross Prentice; Samir M Hanash; Mary L Disis
Journal:  Cancer Prev Res (Phila)       Date:  2012-06-19

Review 2.  Early detection of breast cancer: new biomarker tests on the horizon?

Authors:  Aparna C Jotwani; Julie R Gralow
Journal:  Mol Diagn Ther       Date:  2009-12-01       Impact factor: 4.074

3.  Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer.

Authors:  Karen S Anderson; Niroshan Ramachandran; Jessica Wong; Jacob V Raphael; Eugenie Hainsworth; Gokhan Demirkan; Daniel Cramer; Dina Aronzon; F Stephen Hodi; Lyndsay Harris; Tanya Logvinenko; Joshua LaBaer
Journal:  J Proteome Res       Date:  2008-02-27       Impact factor: 4.466

Review 4.  Can serum autoantibodies be a potential early detection biomarker for breast cancer in women? A diagnostic test accuracy review and meta-analysis.

Authors:  Thejas Kathrikolly; Sreekumaran N Nair; Aju Mathew; Prakash P U Saxena; Suma Nair
Journal:  Syst Rev       Date:  2022-10-09

5.  Autoantibodies in Early Detection of Breast Cancer.

Authors:  Femina Rauf; Karen S Anderson; Joshua LaBaer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-09-29       Impact factor: 4.254
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.